Real World Lecanemab Outcome Data at 6 months in an Academic Healthcare System
In the interim analysis, a trend toward improved depression and anxiety scores over 6 months was observed with modest declines in cognition and performance. A full data set analysis will provide comprehensive data relating to clinical outcomes with mAb treatments. Further analysis of longitudinal data is necessary to confirm whether anti-amyloid monoclonal antibody clinical trial efficacy translates into real world clinical effectiveness at 12 and 18 months.
Authors
- Thomas J. Grabowski (ORCID: https://orcid.org/0000-0002-7425-6610)
- Michael Rosenbloom (ORCID: https://orcid.org/0000-0002-2768-9501)
- Kelania Jimenez
- Varun Mehta
Institutions
- Allen Institute for Brain Science (US)
- University of Wisconsin–Madison (US)
- University of Washington (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70861_108466
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00